Spread | 0.07 | ||||
Long position overnight fee Long position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
Overnight fee time | 21:00 (UTC) | ||||
Currency | USD | ||||
Min traded quantity | 1 | ||||
Margin | 20 | ||||
Stock exchange | United States of America | ||||
Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
Prev. Close | 4.57 |
Open | 4.48 |
1-Year Change | 144.81% |
Day's Range | 4.48 - 4.65 |
Savara Inc. is a clinical stage company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.
BRIEF: For the nine months ended 30 September 2021, Savara Inc revenues decreased from $256K to $0K. Net loss decreased 12% to $31.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and development - Balancing val decrease of 13% to $20.4M (expense), Stock-based Compensation in SGA decrease of 51% to $1.5M (expense), Selling.
Common Stock $.001 Par, 12/11, 500M auth., 47,715,709 issd. Insiders own approx. 0.08% . IPO: N/A. PO: 11/02/06, 14,545,000 shs. @ $2.75 per share by ThinkEquity Partners LLC & Fortis Securities LLC. 04/10, 1-for-25 reverse split.